Previous 10 | Next 10 |
Wells Fargo has downgraded Hyperfine ( NASDAQ: HYPR ) to equal weight from overweight following disappointing Q2 2022 results Wednesday that included lowering guidance . The firm also cut its price target to $2.40 from $8 (~29% upside based on Wednesday's close). T...
Gainers: T2 Biosystems ( TTOO ) +73% . Veru ( VERU ) +38% . Ginkgo Bioworks ( DNA ) +21% . Inotiv ( NOTV ) +20% . Accuray ( ARAY ) +17% . Losers: Athenex ( ATNX ) -46% . Invitae ( NVTA ) -43% . Cer...
Athenex ( ATNX ) -41% on pricing $30M in stock and warrants offering . Invitae ( NVTA ) -25% . Hyperfine ( HYPR ) -17% on Q2 earnings release . Sonos ( SONO ) -17% on Q3 earnings release . Six Flags Entertainment ( SIX ) ...
Hyperfine, Inc. (HYPR) Q2 2022 Earnings Conference Call August 10, 2022, 16:30 PM ET Company Participants Marissa Bych - Gilmartin Group LLC Scott Huennekens - Interim President and Chief Executive Officer Alok Gupta - Chief Financial Officer Conference Cal...
Hyperfine press release ( NASDAQ: HYPR ): Q2 GAAP EPS of -$0.33 misses by $0.06 . Revenue of $1.53M (+337.1% Y/Y) misses by $0.47M . For further details see: Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M
GUILFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference cal...
Virax Biolabs Group ( VRAX ) +40% on launch of real-time PCR test for monkeypox in Europe. 36Kr Holdings ( KRKR ) +14% . InflaRx ( IFRX ) +12% Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Crit...
GUILFORD, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the second quarter 2022 on Wednesday, August 10, 2022. Comp...
AUSTIN, Texas, July 14, 2022 (GLOBE NEWSWIRE) -- Today, at HA Connect!, the 17th annual national conference on hydrocephalus, Hyperfine—creator of Swoop ®, the first FDA-cleared portable magnetic resonance imaging (MRI) device—announced a new software enhancement ...
The following slide deck was published by Hyperfine, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Hyperfine, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list. Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared porta...
The publication includes a subset of data from the ACTION PMR stroke study and provides early evidence that the Swoop ® system is a promising tool for enabling critical stroke treatment choices in urgent care settings. Hyperfine (Nasdaq: HYPR), the groundbreaking health technol...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the second ...